## **AvMed**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

<u>Drug Requested</u>: Cimzia<sup>®</sup> SQ (certolizumab) (Pharmacy)

MEMBER & PRESCRIBER INFOR	RMATION: Authorization may be delayed if incomplete.			
Member Name:				
Member AvMed #:	Date of Birth:			
Prescriber Name:				
Prescriber Signature:				
Office Contact Name:				
Phone Number:	one Number: Fax Number:			
DEA OR NPI #:				
DRUG INFORMATION: Authorization	n may be delayed if incomplete.			
Drug Form/Strength:				
Dosing Schedule:	Length of Therapy:			
Diagnosis:	ICD Code, if applicable:			
Weight:	Date:			
immunomodulator (e.g., Dupixent, Entyvio, Hu	concomitant therapy with more than one biologic umira, Rinvoq, Stelara) prescribed for the same or different nal. Safety and efficacy of these combinations has <b>NOT</b> been			
<b>CLINICAL CRITERIA</b> : Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied. <b>Check the diagnosis below that applies.</b>				
□ Diagnosis: Moderate-to-Severe C	rohn's disease (CD)			
☐ Member has a diagnosis of moderate-to-severe Crohn's disease				
☐ Prescribed by or in consultation with a	Gastroenterologist			

(Continued on next page)

	Member meets <b>ONE</b> of the following:					
		□ 5-aminosalicylates (	balsalazide, olsalazine, sulfasa	alazine)		
		oral mesalamine (Apriso, Asacol/HD, Delzicol, Lialda, Pentasa)				
	Me	Member meets <b>ONE</b> of the following:				
	<ul> <li>□ Member tried and failed, has a contraindication, or intolerance to <u>ONE</u> of the following <u>PREFERRED</u> adalimumab products:</li> <li>□ Humira<sup>®</sup></li> </ul>					
		□ Cyltezo <sup>®</sup>				
		☐ Hyrimoz <sup>®</sup>				
	☐ Member has been established on Cimzia® for at least 90 days <u>AND</u> prescription claims history indicates <u>at least a 90-day supply of Cimzia was dispensed within the past 130 days</u> (verified b					
		chart notes or pharma		pensed within the pas	at 150 days (verified by	
	enare notes of pharmacy para claims)					
u D	iag	gnosis: Active Psoria	ntic Arthritis			
	Member has a diagnosis of active <b>psoriatic arthritis</b>					
	Prescribed by or in consultation with a <b>Rheumatologist</b>					
		onths		ı		
	□ cyclosporine					
	□ methotrexate					
		sulfasalazine				
	Me	ember meets <b>ONE</b> of the	following:			
	☐ Member tried and failed, has a contraindication, or intolerance to <b>TWO</b> of the <b>PREFERRED</b>				ne <b>PREFERRED</b>	
biologics below (verified by chart notes or pharmacy paid claims):						
		□ adalimumab product: Humira <sup>®</sup> , Cyltezo <sup>®</sup>	□ Enbrel <sup>®</sup>	□ Otezla <sup>®</sup>	□ Rinvoq®	
			□ Skyrizi <sup>®</sup>	□ Stelara <sup>®</sup>	□ Taltz <sup>®</sup>	
		or Hyrimoz®	□ Tremfya <sup>®</sup>	☐ Xeljanz <sup>®</sup> /XR <sup>®</sup>		
			lished on Cimzia <sup>®</sup> for at least 9 lay supply of Cimzia was dis	•	•	

(Continued on next page)

chart notes or pharmacy paid claims)

□ Diagnosis: Moderate-to-Severe Rheumatoid Arthritis					
	☐ Member has a diagnosis of moderate-to-severe <b>rheumatoid arthritis</b>				
	Pre	scribe	d by or in consu	ultation with a Rheumatologist	
	☐ Member has tried and failed at least <u>ONE</u> of the following <b>DMARD</b> therapies for at least <u>three (3)</u> months				
		hydro	oxychloroquine		
		leflun	nomide		
		metho	otrexate		
		sulfas	salazine		
	Member meets <b>ONE</b> of the following:				
	☐ Member tried and failed, has a contraindication, or intolerance to <b>TWO</b> of the <b>PREFERRED</b> biologics below (verified by chart notes or pharmacy paid claims):				
			Actemra® SC	☐ adalimumab product: Humira®, Cyltezo® or Hyrimoz®	□ Enbrel <sup>®</sup>
		□ F	Rinvoq®	□ Xeljanz <sup>®</sup> /XR <sup>®</sup>	
		indica	ates <u>at least a 90</u>	ablished on Cimzia <sup>®</sup> for at least 90 days <u>AND</u> prescription clands of Cimzia was dispensed within the past 130 macy paid claims)	•
□ D	iag	nosis	: Active Non	-Radiographic Axial Spondyloarthritis	
	Me	mber	has a diagnosis	of active non-radiographic axial spondyloarthritis	
	☐ Prescribed by or in consultation with a <b>Rheumatologist</b>				
	□ C-reactive protein [CRP] levels above the upper limit of normal				
	□ Sacroiliitis on magnetic resonance imaging [MRI] (indicative of inflammatory disease, but without definitive radiographic evidence of structural damage on sacroiliac joints)				
	Member tried and failed, has a contraindication, or intolerance to <b>TWO</b> NSAIDs				
□ Diagnosis: Ankylosing Spondylitis					
	Me	mber	has a diagnosis	of ankylosing spondylitis	
	Member tried and failed, has a contraindication, or intolerance to <b>TWO</b> NSAIDs				
_				, to <u>- 1, 0</u> 1, 0 1	

(Continued on next page)

	<ul> <li>□ Member meets <u>ONE</u> of the following:</li> <li>□ Member tried and failed, has a contraindication, or intolerance to <u>TWO</u> of the <u>PREFERRED</u> biologics below (verified by chart notes or pharmacy paid claims):</li> </ul>					
		adalimumab product: Humira®, Cyltezo	o® or Hyrimoz®	□ Enbrel <sup>®</sup>	□ Rinvoq®	
		□ Taltz <sup>®</sup>		□ Xeljanz <sup>®</sup> /XR	®	
	Member has been established on Cimzia <sup>®</sup> for at least 90 days <u>AND</u> prescription claims history indicates <u>at least a 90-day supply of Cimzia was dispensed within the past 130 days</u> (verified b chart notes or pharmacy paid claims)					
□ D	iag	nosis: Moderate-to-Severe Plaque F	Psoriasis			
	☐ Member has a diagnosis of moderate-to-severe <b>plaque psoriasis</b>					
	Pre	scribed by or in consultation with a Dermat	ologist			
	☐ Member tried and failed at least <u>ONE</u> of either Phototherapy or Alternative Systemic Therapy for at least <u>three (3) months</u> (check each tried below):					
		Phototherapy:	□ Alternat	ive Systemic Ther	apy:	
		☐ UV Light Therapy	□ Oral	□ Oral Medications		
	□ NB UV-B		□ acitretin			
		□ PUVA				
				yclosporine		
	Me	mber meets <b>ONE</b> of the following:				
Member tried and failed, has a contraindication, or intolerance to <b>TWO</b> of the <b>PREFERRED</b> biologics below (verified by chart notes or pharmacy paid claims):						
		□ adalimumab product:	Enbrel®	□ Otezla®	□ Skyrizi <sup>®</sup>	
		Humira <sup>®</sup> , Cyltezo <sup>®</sup> or Hyrimoz <sup>®</sup>	Stelara <sup>®</sup>	□ Taltz <sup>®</sup>	□ Tremfya <sup>®</sup>	
		Member has been established on Cimzia <sup>®</sup> for indicates at least a 90-day supply of Cimz chart notes or pharmacy paid claims)	-		=	
Med	icat	ion being provided by a Specialty P	harmacy – Pr	oprium Rx		
			•			

\*\*Use of samples to initiate therapy does not meet step edit/preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*